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Mutation of the PIG-A gene in hematopoietic stem cells (HSCs) results in the loss of 
glycosylphosphatidylinositol-anchored proteins (GPI-APs) on HSCs, but minimally 
affects their development, and thus can be used as a clonal maker of HSCs. We analyzed 
GPI-APs expression on six major lineage cells in a total of 574 patients with bone 
marrow (BM) failure in which microenvironment itself is thought to be unaffected, 
including aplastic anemia (AA) or myelodysplastic syndrome (MDS). 
GPI-APs-deficient (GPI-APs-) cells were detected in 250 patients. Whereas the 
GPI-APs- cells were seen in all six lineages in a majority of patients who had higher 
proportion (≧3%) of GPI-APs- cells, they were detected in only limited lineages in 
92.9% of cases in the lower proportion (<3%) group. In all 250 cases, the same lineages 
of GPI-APs- cells were detected even after 6-18 month intervals, indicating that the 
GPI-APs- cells reflect hematopioesis maintained by a self-renewing HSC in most of 
cases. The frequency of clones with limited lineages seen in mild cases of AA was 
similar to that in severe cases, and clones with limited lineages were seen even in two 
health volunteer cases. These results strongly suggest most individual HSCs produce 
only restricted lineages even in a steady state. While this restriction could reflect 
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heterogeneity in the developmental potential of HSCs, we propose an alternative model 
in which the BM microenvironment is mosaic in supporting commitment of progenitors 
towards distinct lineages. Our computer simulation based on this model successfully 
recapitulated the observed clinical data. 
 
Introduction 
To sustain hematopoiesis, hematopoietic stem cells (HSCs) must, on the one hand, 
replenish themselves by self-renewal and on the other hand produce differentiating 
progenitor cells. It is also known that most HSCs remain dormant and are only rarely 
and randomly activated. It has been estimated that each human possesses a total of 104 
HSCs, and that ~400 HSCs actively contribute to hematopoiesis, replicating once per 
year1, 2. However, the actual dynamics of hematopoiesis by HSCs remains uncertain. 
For example, it is unclear how long an individual HSC maintains hematopoiesis and 
whether all major lineage cells are produced from a single HSC. These issues have been 
difficult to address due to the lack of appropriate experimental systems, regardless of 
animal species. 
   In the case of humans, however, we were led to consider one “experiment of nature” 
that makes it possible to track the progeny of a HSC; i.e. by detecting blood cells 
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deficient in glycosylphosphatidylinositol-anchored proteins (GPI-APs) using flow 
cytometry. GPI-APs-deficient (GPI-APs-) blood cells are rarely detectable in healthy 
individuals, but are a common feature in paroxysmal nocturnal hemoglobinuria (PNH) 
and are also frequently seen in patients with bone marrow (BM) failure such as AA or 
MDS. These cells are known to be derived from HSCs with a mutation in the 
phosphatidylinositol N-acetylglucosaminyltransferase subunit A (PIG-A) gene. MDS 
cases harboring GPI-APs- blood cells are characterized by polyclonal hematopoiesis and 
good response to immunosuppressive therapy, and are therefore thought to be similar to 
AA in their pathophysiology3.   
  The PIG-A mutant HSCs used to be thought to have greater proliferative capacity 
than normal HSCs because one or a few PIG-A mutant clones sometimes account for a 
large proportion of hematopoietic cells for long period in PNH patients4. However, 
several reports instead indicate that the mutant HSCs in most PNH patients have 
properties similar to normal HSCs: e.g. no growth advantage over wild-type HSCs5,6, 
genetic stability and extremely low incidence of secondary mutations2, 7-9, and the rarity 
of leukemic cell evolution of GPI-APs- cells in PNH patients10.   
  We recently found that GPI-APs- cells in patients with AA and MDS frequently show 
various patterns in the proportion of granulocytes and erythrocytes and that the 
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individual patterns of the two lineage combinations can persist for many years. The 
percentage of GPI-APs- cells in some patients remained almost the same over 10 years 
even when the percentages were less than 1%11. In such stable cases, it is quite likely 
that GPI-APs- peripheral blood cells are produced from HSC(s), and that the GPI-APs- 
HSC itself as well as its surrounding environment is largely normal, at least during the 
observation period. Indeed, BM environment itself in the patients to support 
hematopoiesis is thought to be largely normal, since these cases are thought to be 
caused by immune reaction against blood cells. It is also highly probable that the whole 
GPI-APs- cells in each patient represent a clone, originating from a single HSC in which 
PIG-A mutation occurred, since it is statistically rare that the PIG-A mutation occurs 
twice in one patient. Although it is unclear that such a clone is maintained by a single 
HSC or multiple descendent HSCs, it can be said that the kinetics of GPI-APs- cells 
during stable period reflect the regular hematopoietic events originally initiated by a 
single HSC. We then thought that it could be very much informative if we extend our 
analysis to cover various hematopoietic lineages in addition to erythrocytes and 
granulocytes. We therefore determined the proportion of GPI-APs- cells in six major 
lineages, namely granulocytes (G), monocytes (M), erythrocytes (E), T cells (T), NK 
cells (NK) and B cells (B), in peripheral blood (PB) cells from BM failure patients 
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using a highly sensitivity flow cytometric analysis12.  
 
Materials and Methods 
Patients and healthy volunteers 
The PB of 574 patients with various types of cytopenias was examined for the presence 
of GPI-APs- cells using high sensitivity flow cytometry. Their diagnoses included AA in 
354 (39 with very severe, 92 with severe, and 223 with non-severe AA13), 
MDS-refractory anemia (RA) defined by the FAB classification14 in 207, and classic 
PNH in 13. The male to female ratio was 1: 1.2 (261:313) and the median age was 57 
years (range: 1 to 95 years). PB samples from 192 healthy individuals were also 
examined for the presence of GPI-APs- cells in all lineages of cells. All patients and 
healthy individuals including next of kin on the behalf of minors/ children participants 
in our study provided their informed written consent before sampling. This study 
protocol was approved by the ethics committee of Kanazawa University Graduate 
School of Medical Science. 
 
Monoclonal antibodies (mAbs) 
mAbs used for multicolor flow cytometry were; anti-CD59 labeled with FITC (P282E, 
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IgG2a; Beckman Coulter, Miami, FL), anti-CD55 labeled with FITC (IA10, IgG2a; BD 
Pharmingen), anti-CD48 labeled with FITC (J4-57, IgG1; Beckman Coulter), 
anti-CD33 labeled with APC (D3HL60.251, IgG1; Beckman Coulter), anti-CD19 
labeled with APC-Cy7 (SJ25C1, IgG1; BD Pharmingen), anti-CD335 labeled with PE 
(BAB281, IgG1; Beckman Coulter), anti-CD3 labeled with PerCP-Cy5.5 (SK7, IgG1; 
BD Pharmingen), anti-CD11b/Mac-1 labeled with PE (ICRF44, IgG1; BD Pharmingen), 
anti-glycophorin A labeled with PE (JC159, IgG1; Dako, Carpenteria, CA).  
 
Flow cytometry for detecting GPI-APs- cells 
Six lineages of blood cells including granulocytes, erythrocytes, monocytes, T cells, B 
cells and NK cells were subjected to high sensitivity flow cytometry for detecting small 
populations of GPI-APs- cells. All blood samples were analyzed within 24 h to avoid 
false positive results due to cell damage. The staining with the each mAb in this study 
was performed according to the well-established lyse-stain protocol, previously 
described in detail12, 15. Briefly, 3 to 5 mL of heparinized blood was drawn from the 
patients and healthy individuals. Erythrocytes were lysed in a lysis buffer containing 
NH4Cl 8.26 g/L, KHCO3 1.0 g/L, and EDTA · E4Na 0.037 g/L to detect 
GPI-APs- leukocytes. After washing with saline, 50 µL of the leukocyte suspension was 
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incubated with FITC-labeled anti-CD55 and anti-CD59 mAbs for granulocytes or 
FITC-labeled anti-CD48 and anti-CD59 mAbs for monocytes, T cells, B cells and NK 
cells in combination with mAbs specific for lineage markers including PE-labeled 
CD11b for granulocytes, APC-labeled CD33 for monocytes, PerCP-Cy5.5 labeled CD3 
for T cells, APC-Cy7 labeled CD19 for B cells and PE labeled CD335 for NK cells. 
Fresh blood was diluted to 3% in phosphate-buffered saline (PBS), and then 50 µL was 
incubated with PE-labeled anti-glycophorin A and FITC-labeled anti-CD55 and 
anti-CD59 mAbs on ice for 30 minutes to detect GPI-APs- erythrocytes. Three-step 
gating excluded debris and immature granulocytes that are frequently found in samples 
from patients with MDS. Step 1 involved the gating of granulocyte, lymphocyte or 
monocyte populations from the FSC-SSC scattergrams (R1). Step 2 involved the gating 
of the lineage markerbright population on the lineage marker-SSC scattergram to exclude 
the lineage markerdim cells that are features of either damaged cells or immature cells. 
Step 3 was the gating of R1 × R2 and the analysis of 106 cells on R1 × R2 scattergrams. 
The following cut-off values that had been determined by our previous studies based on 
183 healthy individuals were used; the presence of ≥0.005% CD55−CD59− glycophorin 
A+ erythrocytes, ≥0.003% CD55−CD59−CD11b+ granulocytes, and ≥0.01% 
CD48−CD59− CD33+ monocytes, CD48−CD59− CD3+ T cells, CD48−CD59−CD19+ B 
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cells and CD48−CD59−CD335+ NK cells 12, 16. When GPI-APs- cells were detected in 
only one lineage of cells or the percentages of GPI-APs- cells were less than 0.01%, 
then additional samples were tested, and the patients were judged to be positive for 
increased GPI-APs- (PNH+) when the analysis results of the first and second samples 
were identical.  
  Data acquisition was performed immediately after the sample preparation using a 
FACSCanto II® instrument (Beckton Dickinson) and the data were analyzed using the 
FACSDiva software program and the percentage of each population was calculated by 
FlowJo software 7.6.1 (Tree star, Inc. Ashland, OR).  
 
Cell sorting and PIG-A gene analysis 
Freshly isolated GPI-APs- cells were separated from GPI-APs+ fraction using a 
FACSAria II® instrument (Beckton Dickinson). More than 95% of the sorted cells were 
GPI-APs deficient. An analysis of the PIG-A gene mutation was performed as described 
previously17. Briefly, the coding regions of PIG-A were amplified by nested or 
semi-nested PCR using 12 primer sets, and 6 ligation reactions were used to transform 
competent Escherichia coli JM109 cells (Nippon Gene, Japan). Five clones were 
selected randomly from each group of transfectants and subjected to sequencing with 
9 
 
BigDye Terminator v3.1 Cycle Sequencing kit (Applied Biosystems, San Diego, CA) 
and an ABI PRISM 3100 Genetic Analyzer (Applied Biosystems). 
 
Simulation of the blood cell production by HSCs 
Migration, division, lineage determination and death of clones of a HSC in BM 
environment are simulated with a lattice Monte Carlo method. For efficient simulation, 
we focused on the events on a cross-section of BM, which enabled us to perform 
two-dimensional simulation. The occurrence of events was managed with their 
transition probabilities and the simulation was executed on the basis of actual time.  
We employed the hybrid null-event Monte Carlo algorithm18, 19, and here outline the 
model description and simulation setup (Also see Supplementary Note for detailed 
information). A square area (30 mm×30 mm) that is large enough to encompass some 
commitment planes is represented using 1500×1500 square lattices (20 µm×20 µm 
each). Initially, a HSC is randomly added to a site, and then it continues to create clones 
once per 10 hours until there have been five divisions. Clones randomly move along the 
lattice with the transition probability, and undergo cell division once per 8-12 hours. We 
assume that lineage determination occurs after the fifth division, based on the site of the 
clone in the mosaic-like hematopoietic environment where each site supports 
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differentiation into M, E, B or T cell lineages. In addition, the lineage clone becomes a 
mature cell after a further five divisions under the condition that it can divide only in the 
sites that support differentiation into the same lineage. Otherwise cell death results after 
48-hour movement on areas that support other lineages, although all clones die 72 hours 
after maturation. 
  We also investigated the relation between clone size and the number of emerging cell 
lineages. In our simulation, clone size is dominated by the setting of "N times divisions 
for lineage determination and further N times divisions for maturing". We simply 
change the number N in a range of 3-12. For each N, 128 simulations starting from 
randomly selected initial sites of HSCs are executed for 120 simulation hours. For each 
simulation, the number of cell lineages is counted, and clone size is calculated as the 
maximum number of clones for the entire simulation period. 
 
Results 
GPI-APs- cells were seen in various combination of lineages of blood cells from BM 
failure patients 
Of 574 patients with BM failure, GPI-APs- cells were detected in at least one lineage of 
cells of 250 patients (44%). The prevalences of increased GPI-APs- cells were 56% in 
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AA and 19% in MDS-RA. The proportion of GPI-APs- cells among granulocytes ranged 
0.003% to 99.1%, with mean and median value 5.38% and 0.19% respectively. 
GPI-APs- cells were rather frequently found in patients with less severe AA; the 
prevalences were 63% in non-severe, 49% in severe, and 31% in very severe AA 
patients. The lineage combinations of GPI-APs- cells in patients possessing GPI-APs- 
cells (PNH+ patients) were classified into 16 different patterns (Supplementary Table 1). 
Figure 1 shows representative flow cytometric profiles of one healthy individual and 4 
patients showing GMETNKB, GME, GMETNK or GMEB patterns. 
 
Clone size of GPI-APs- granulocytes correlates with the number of cell lineages 
that contain GPI-APs- cells 
The percentages of GPI-APs- granulocytes in each group bearing GPI-APs- cells in 1 to 
6 lineages are plotted in Figure 2. There was a clear trend toward the pattern of the 
higher the percentage of GPI-APs- granulocytes in patients, the greater the number of 
GPI-APs- cell lineages.  
  In order to closely examine the relationship between the severity of AA and the 
GPI-APs- clone size, we arbitrarily classified AA patients in this study into five 
categories, namely stage 1, 2 and 3 (non severe) , stage 4 (severe), and stage 5 (very 
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severe), based on the severity of cytopenias (Supplementary Table 2) and replotted the 
data (Figure 2B). Patients with higher proportion (>1%) of GPI-APs- granulocytes were 
not seen in non severe cases, suggesting that the clone size of GPI-APs- cells correlates 
with severity of BM failure. The notable observation here is that the correlation between 
the percentage of GPI-APs- granulocytes and the number of GPI-APs- cell lineages is 
almost identical in all three groups. This finding may indicate that the production of 
limited lineage cells observed in smaller clones is not due to the possible functional 
failures of BM microenvironment. It seems more likely that “fewer lineages in smaller 
clones” instead represents events occurring in normal hematopoiesis. 
 
Persistence of GPI-APs- lineage combination over a long period 
We then reexamined PB cells of 250 patients 6 to 18 months after the first examination 
and to our surprise, GPI-APs- cells were observed in all 250 patients. Detection of 
GPI-APs- cells after such a long interval indicates that the GPI-APs- cells are most 
likely derived from HSCs rather than from non-self-renewing progenitors. Of special 
interest was our finding that in all 250 cases, the same combinations of lineages were 
detected regardless of the interval between the first and second analysis. Flow 
cytometric profiles of various lineages of a case representing GMET type are shown in 
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Figure 3. Figure 4 shows the proportion of GPI-APs- cells in each lineage in the first 
and second analysis for a total of representative 25 cases (5 cases for each type). 
 
PIG-A gene mutations in different lineages of blood cells 
To confirm their clonal origin, GPI-APs- cells sorted from 5 patients were subjected to 
PIG-A gene analysis. The same mutation was identified in different lineages in 3 
patients (Supplementary Table 3). In GPI-APs- granulocytes with other lineages from 
Patients 16, 1 and 5 and GPI-APs- granulocytes from Patients 9 and 30, the same 
mutation was found 3 to 7 months after the initial analyses. Therefore, it is highly 
probable that in most, if not all, cases the GPI-APs- cells are clonal20. This finding is in 
line with the estimation that PNH patients only rarely have more than two clones at the 
HSC level8, 9. 
 
GPI-APs- cells were detected in limited lineages in healthy volunteers over a long 
period 
Dormant HSCs with PIG-A mutation reside in the BM and can be activated albeit 
uncommonly17. If this hypothesis is tenable, small populations of GPI-APs- cells may be 
detectable in some healthy individuals. We then examined PB of 192 healthy volunteers 
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for the presence of GPI-APs- cells. Notably, two were found to bear detectable levels of 
GPI-APs- cells, and in both of them GPI-APs- cells were detected in limited lineages, 
representing GME and GE type (Figure 5A). The two healthy cases bearing GPI-APs- 
cells were situated within the range of distribution of AA and MDS cases in terms of 
chimerism ratio vs. lineage number (Figure 5B), further supporting that findings seen in 
AA and MDS cases reflect normal hematopoiesis. 
  As described in Introduction section, the number of active human HSCs at any given 
time is estimated to be around 400. It is therefore likely that the GPI-APs- clones with a 
frequency of less than 0.25% reflect hematopoiesis maintained by a single HSC. It is 
clear from our studies that most of these small clones contain only limited lineage cells. 
Even in the case of larger clones, e.g. clones of 1-3% chimerism that might be 
maintained more than two HSCs, the majority (81%) are non-full-lineage clones. 
Collectively, these results indicate that most individual human HSCs only give rise to a 
limited range of hematopoietic progeny. 
 
A model for the hematopoietic microenvironment to explain the production of 
limited cell lineages from a HSC 
A cogent explanation for this phenomenon may have important implications for normal 
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hematopoiesis. We considered several possible explanations such as; (a) the limited 
lineage spectrum of progeny cells may reflect the presence of progenitors with equally 
limited potential, (b) HSCs are intrinsically heterogeneous in terms of developmental 
potential, (c) BM environment is heterogeneous in its ability to support the 
differentiation of distinct lineages. However, as will be discussed later, these cases 
seemed quite unlikely. 
  Instead of above ideas, we came to think that the unexpected production of limited 
cell lineages by HSCs may be explained by assuming the presence of mosaic-like 
hematopoietic environments that can differently support the “commitment” of early 
multipotent progenitors to a certain lineage. 
  We attempted to test this idea by modeling and simulation. For simplicity, 
granulocytes and monocytes are placed into the myeloid lineage while T and NK cells 
are placed into the T lineage, consequently all lineages being classified into M, E, T, B 
lineages. The clinically observed data for chimerism ratio and detected lineages shown 
in Figure 2A are re-plotted in Figure 6A. For cases where the proportion of GPI-APs- 
clones is between 0.3 and 3% (representing typical size clones), the frequencies of 
different lineage combinations are shown in Figure 6B. 
  We assume that a self-renewing HSC is located in a particular location in BM and 
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that uncommitted progenitors derived from this HSC can reach to a certain defined area 
(Figure 6C), which we term here the “commitment sphere” (see also Supplementary 
Note for detailed information). If the BM microenvironment is mosaic in terms of 
function in inducing the commitment of progenitors towards a certain lineage, and the 
size of such mosaic is as large as commitment sphere, then production of progenitors of 
limited lineages can occur. 
  In our model, it is critical to determine how the mosaic-like environment is 
distributed in BM. To this end, we comprehensively examined 112 kinds of mosaic 
patterns, varying grains of area ratios among commitment areas supporting M, E, B and 
T. The strategy to generate the patterns is summarized in the Supplementary Note.  For 
each mosaic pattern out of 112 variants, we simulated that a single randomly located 
HSC in certain type of mosaic environment undergoes a certain round of cell division, 
and then undergo commitment according to the place they are located. After 
commitment, cells further make proliferation and finally terminal differentiation to form 
mature blood cells. For simplicity, the number of cell division before and after 
commitment is set as 5 and 5, respectively, in the simulation. We then investigated 
which cell lineages appeared, counting the number of cells belonging to each lineage. A 
total of 100 clones were simulated for each mosaic pattern. We found that simulation 
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based on 17 mosaic patterns resulted in histograms similar to the clinical data. Figure 
6C shows a representative mosaic among them, and Figure 6D shows the histogram for 
the results of simulations in which a total of 256 of randomly located HSCs gave rise to 
hematopoietic colonies in the mosaic pattern shown in Figure 6C, which recapitulate the 
clinical results (Figure 6B). We also performed simulations of many virtual HSCs in the 
same mosaic environment while changing clone size (i.e. changing the cell division 
times before and after commitment, e.g. 3-3, 4-4, 5-5, 6-6, 7-7, resulting in the change 
in the size of the commitment sphere and the colony of mature cells). The relationship 
between clone size and number of lineages in each clone was then plotted in Figure 6E, 
which looks quite similar to Figure 6A. Thus, these simulations may have provided a 
reasonable explanation for the observed in vivo findings. 
   In the simulation, we assumed that T/NK cell progenitors and B cell progenitors are 
generated in distinct sites. If the induction site for T/NK cell progenitors is assumed to 
completely overlap or to be included as a part of B cell progenitor induction site (Figure 
7A and B), our simulation predicts that “MET” type clones would hardly be generated 
(Figure 7C and D), which is not the actual case. Therefore, our in vivo findings together 
with the results of simulation strongly suggest that T/NK cell progenitors are produced 




In the present study, by flow cytometrically detecting GPI-APs- cells in major six blood 
lineages, we have succeeded in visualizing the dynamics of individual HSCs in bone 
marrow failure patients. The results strongly suggest that most individual human HSCs 
only give rise to a limited range of hematopoietic progeny even in regular 
hematopoiesis.  
  We thought that we should provide a reasonable explanation for this unexpected 
finding i.e. the detection of GPI- APs- cells in the limited lineages over long period. 
Before we reach to our model, we have considered several possibilities to explain this 
finding, as briefly mentioned in the Result. Here we will discuss these possibilities, (a), 
(b), and (c). 
(a) One possibility is that the limited lineage spectrum of progeny cells may reflect the 
presence of progenitors with equally limited potential. Indeed, in contrast to classical 
models of hematopoiesis, which assume the early segregation of HSCs to 
myelo-erythroid lineage and lymphoid lineage, some recent revised models of both 
mouse and human hematopoiesis have proposed that myeloid lineages are also derived 
from lymphoid branches21, 22. However, implications of these models in the present 
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study seem unlikely, since, as mentioned earlier, it is clear that most cases represent 
activities of self-renewing HSCs.  
(b) Another simple explanation might be that HSCs are intrinsically heterogeneous in 
terms of developmental potential. Recent studies have shown such heterogeneity in 
murine HSCs, some being prone to produce myeloid cells while others to produce 
lymphoid cells23-28. However, it seems quite unlikely that HSC intrinsically have as 
many as 16 different subtypes as shown in Supplementary Table 1. 
(c) It is also possible that the BM environment is heterogeneous in its ability to support 
the differentiation of distinct lineages. However, this is also quite unlikely. Provided that 
400 stem cells contribute to whole hematopoiesis1, 2 containing 18 x 1011 hematopoitic 
cells29 in a total of about 1 kg active BM mass30, the size of the hematopoietic site of 
one clone maintained by a single HSC in BM could be several cm3, which may contain 
on the order of 109 hematopoietic cells and a comparable number of stromal cells. It is 
thus difficult to conceive that such large area contains only limited types of 
microenvironments. 
  Thus, we came to think that the above three explanations were quite unlikely. We 
then came to propose a reasonable model as an explanation of this phenomenon. This 
model assumes that the microenvironment of BM is mosaic in inducing the commitment 
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of progenitors to distinct lineages. If the size of area where uncommitted progenitors 
derived from one HSC can reach (“commitment sphere” in Figure 6C) is similar to the 
size of mosaic compartments, production of limited lineage cells can occur. We named 
our model “mosaic commitment-inducing microenvironment model”. This idea on first 
viewing may sound similar to the idea mentioned above in (c), but clearly different in 
that our model focuses on only commitment-inducing function of microenvironment 
and thus the size of mosaic area is much smaller. In this context, our model is also 
distinct from the classical idea of “hematopoietic inductive microenvironment (HIM)”31, 
which is close to the idea mentioned above in (c).  
  To test whether our model can explain the in vivo findings, we applied a computer 
simulation approach, and simulations based on this model nicely recapitulated the 
observed in vivo findings. We emphasize here that we do not claim that our in vivo 
findings indicate the presence of mosaic commitment-inducing microenvironment in 
BM, but just propose a novel model that can explain the finding which otherwise is 
difficult to explain.  
  We recognize that the issue of whether the dynamics of HSCs observed in this study 
represents normal hematopoiesis must be critically discussed. Since the stable 
production of limited lineages was observed in milder cases of AA patients similarly to 
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more severe cases (Figure 2B), it is likely that these observed dynamics represent 
normal hematopoiesis. Detection of stable GPI-APs- clones producing limited lineages 
in healthy volunteers further supports this notion (Figure 5). 
  Nevertheless, here we will make discussion on the issue whether we are making some 
overestimation or underestimation in the interpretation of data in AA and MDS cases. 
Our findings can be summarized as follows: (i) A single HSC gives rise to a limited 
spectrum of lineage cells, (ii) HSCs stably and continuously produce blood cells by 
years. 
  As for the finding (i), the possibility could exist that GPI-APs- HSCs or progenitors 
have some defect in their migration potential, resulting in a failure to produce the 
complete spectrum of lineages. Although it is difficult to completely rule out this 
possibility, so far no published findings are available that support it. Another possible 
explanation could be that the HSCs in AA or MDS patients are already defective in 
developmental potential, or that the hematopoietic microenvironments in these patients 
are disorganized. However, these may not be critical factors, since detection of 
GPI-APs- cells of limited lineages was similarly seen in milder cases of AA, and also in 
healthy volunteers (Figure 2B, Figure 5). AA and MDS may result from various causes, 
and it has been supposed that a certain proportion of cases are primarily caused by the 
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impaired function of microenvironment. However, it is likely that in most cases in the 
present study the microenvironment itself is largely normal, because all the patients are 
bearing GPI-APs- cells, which is a sign to show that immunological pathophysiology is 
the main cause of the disease. It can also be noted that most AA patients who undergo 
allogeneic BM transplantation achieve complete hematologic recovery despite the fact 
that BM stromal cells are not transplantable32, indicating that the hematopoietic 
microenvironments in AA patients are not impaired. Another possibility to be discussed 
is that the immunological reaction against GPI-APs- HSCs may affect their blood cell 
formation, since AA and MDS cases bearing GPI-APs- cells are thought to be caused by 
such autoimmune activities. However, such effect cannot be essential, since GPI-APs- 
cells are usually out of the target of immune cells, and the autoimmune activities in 
patients tested in this study have been virtually negligible, judging from the fact that the 
clone sizes of GPI-APs- cells in all patients scarcely changed during the observation 
periods.   
    We used antibody for CD55, CD59, or CD48 to positively stain GPI-AP expressing 
cells instead of FLAER that directly stain GPI-APs. In calibration experiments, we have 
seen that both methods virtually made no difference (data not shown). We note here that 
our approach could result in the overestimation of the presence of GPI-APs- cells 
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compared with the FLAER method, since FLAER can cover all GPI-APs. However, 
such overestimation seems to occur at a very low frequency, and moreover, it will never 
cause the underestimation for the presence of GPI-APs- cells.  
  Finding (ii) seems to fit well with the expected dynamics of HSCs. However, this 
finding could result from an overestimation. Since patients have some BM failure, the 
total HSC number may be more or less reduced. In such a less competitive situation, it 
could be that the active HSCs have a better chance to continue hematopoiesis. In 
addition, GPI-APs- cells may have some survival advantage over normal blood cells in 
patients because GPI-APs- cells may be less sensitive to immunological attacks than 
GPI-APs+ cells33. However, in fact, the combination of GPI-APs- lineage as well as the 
proportion of GPI-APs- cells in PB persisted over a long period as it is, indicating that 
most of clones do not have an obvious dominance against other clones. It is also 
important to note that any possible overestimation in HSC longevity does not call into 
question finding (i). 
  Finally, it should be discussed whether such heterogeneity as proposed in our model 
can actually be observed in the BM environment. Heterogeniety of stromal environment 
has been pointed out in early studies for example based on the findings of preferential 
generation of erythroid or granulocytic cells in spleen and BM, respectively31. A recent 
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study has suggested the presence of a microenvironment that selectively supports B cell 
development in murine BM34. This then leads to the question of how large is the 
commitment sphere and mosaic fragments of the BM environment? We do not have any 
data concerning the actual size of the commitment sphere or compartments of mosaic 
environments, but would suggest that the relative size of these two may be similar to 
each other. Thus, each piece of the mosaic could be very small, containing only a few 
stromal cells. We hope that our present report and speculative model will facilitate 
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Figure 1.  Detection of GPI-APs- cells in different lineages of blood cells.  
A. One example of PB cells of a healthy individual having no GPI-APs- cells. B. 
GPI-APs- cell combination patterns in four patients. Profiles of PB cells of patients 
showing GPI-APs- cells in GMETNKB, GME, GMETNK and GMEB lineages are 
shown. Lineage markers used were CD11b for G, CD33 for M, glycophorin-A 
(CD235a) for E, CD3 for T, NKp46 for NK and CD19 for B. G, M, E, T, NK or B stands 
for granulocytes, monocytes, erythrocytes, T cells , NK cells or B cells, respectively. 
 
Figure 2.  Correlation between the clone size of GPI-APs- granulocytes and the 
number of cell lineages that contain GPI-APs- cells. 
A. The percentage of GPI-APs- granulocytes and the number of cell lineages that 
contain GPI-APs- cells in individual patients are plotted. A red line for 0.25% stands for 
the expected value for an average size of a single HSC clone. B. The percentage of 
GPI-APs- granulocytes and the number of cell lineages that contain GPI-APs- cells in 
AA patients, classified in three categories according to the severity of disease (stage 1 or 
2, stage 3, and stage 4 or 5), are plotted. AA patients were classified into five categories 
based on the disease severity (stage 1 or 2, stage 3, and stage 4 or 5) (for details, see 
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Supplementary Table 2).  
 
Figure 3.  The lineage combination pattern of GPI-APs- cells was same at the first 
sampling (A) and after 6 months (B).  
 
Figure 4.  The combination of GPI-APs- lineage as well as the proportion of 
GPI-APs- cells in PB persist over a long period. 
GPI-APs- cells were analyzed in PB of 250 patients twice at intervals ranging 6 months 
to 18 months. The numbers 1 and 2 refer to the first and second analysis. In all cases, 
GPI-APs- cells were detected in the same lineages in both analyses.  Among them, 25 
cases (5 for each type of lineage combination) are shown. Bars represent the proportion 
of GPI-APs- cells in each lineage in PB.   
 
Figure 5.  GPI-APs- cells in healthy individuals.  
A. Two healthy individuals (Healthy 1 and Healthy 2) showed GPI-APs- cells in the 
same lineage combination pattern at the first sampling (i) and 13 and 7 months after the 
first sampling (ii), respectively. B. The percentage of GPI-APs- granulocytes in the two 





Figure 6.  Simulation of HSC differentiation in a model assuming a mosaic 
environment for the commitment of primitive progenitors recapitulates the clinical 
observation. 
A. The percentage of GPI-APs- granulocytes vs. the number of cell lineages in 
individual patients. Data from Figure 2A were re-plotted in a setting where granulocytes 
and monocytes were placed in the myeloid lineage and T and NK cell lineages in the T 
cell lineage. A red line for 0.25% stands for the expected value for an average size of a 
single HSC clone. B. Frequency of clone types among cases where the percentage of 
GPI-APs- granulocytes is between 0.3 to 3 %. C. A model assuming that the BM 
microenvironment is heterogeneous in supporting the commitment of progenitors. A 
certain range where the commitment of progenitors mainly occurs (with a probability of 
>97%) is termed the “commitment sphere” (see Supplementary Note for detailed 
information).  Areas colored by beige, pink, light green, or blue represent the 
environment supporting commitment only towards M, E, T or B, respectively. If a HSC 
happens to reside in a location in which the commitment sphere contains only M and E 
regions, then this HSC can eventually produce only M and E cells, even if committed 
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progenitors expand enormously and become widely scattered. The depicted simulation 
goes as follows: a virtual HSC undergoes several cell divisions at fixed intervals while 
randomly migrating. The uncommitted progenitors then undergo a fate decision based 
on their ultimate location in the commitment sphere. Committed progenitors can also 
randomly move around, but can proliferate only in the lineage specific supporting 
environment.  After several additional fixed time cell divisions as committed 
progenitors, cells become mature and lineage restricted. D. One example illustrating the 
frequency of clone types simulated as shown in (C). A total of 100 virtual HSCs were 
simulated to form hematopoietic clones, and numbers of the resulting clone types are 
illustrated (Supplementary movies. 1-5). E. Simulation of individual HCSs for size and 
number of progeny lineages. The simulation well recapitulated the clinical observations 
shown in (A). 
 
Figure 7.  Alternative conditions for induction sites to T and B cell lineages. 
Illustration of a mosaic pattern in a case where the induction site to the T lineage 
completely (A) or partially (B) overlaps with the B lineage (i.e. green area is for both T 
and B in (A), while blue are for T and green area for B in (B)). C and D. Histograms 




Supplementary Table Legends 
Table S1.  Classification of 16 different GPI-APs- cells patterns. 
The lineage combinations of GPI-APs- cells in patients possessing GPI-APs- cells were 
classified into 16 different patterns. 
 
Table S2.  Definition of the AA severity. 
We arbitrarily classified AA patients into five categories, namely stage 1, 2 and 3 (non 
severe), stage 4 (severe), and stage 5 (very severe), based on the severity of cytopenias.   
 
Table S3.  PIG-A gene mutations in each GPI-APs- cell population. 
To confirm the clonal origin, GPI-APs- cells sorted from 5 patients were subjected to 




Supplementary Movie Legends 
Movie S1.    
Results as described in the supplementary note_Supplementary_Movie_1_for lineage 
type of METB.   
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 Movie S2.   
Results as described in the supplementary note_Supplementary_Movie_2_for lineage 
type of MET.   
 
Movie S3.   
Results as described in the supplementary note_Supplementary_Movie_3_for lineage 
type of MEB.   
 
Movie S4.   
Results as described in the supplementary note_Supplementary_Movie_4_for lineage 
type of ME.   
 
Movie S5. 
Results as described in the supplementary note_Supplementary_Movie_5_for lineage 
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Figure 1. Detection of GPI-APs- cells in different lineages of blood cells. 
Figure 2. Correlation between the clone size of GPI-APs- granulocytes and the number of 
cell lineages that contain GPI-APs- cells. 
Figure 3. The lineage combination pattern of GPI-APs- cells was same at the first sampling 
(A) and after 6 months (B). 
Figure 4. The combination of GPI-APs- lineage as well as the proportion of GPI-APs- cells 
in PB persist over a long period. 
Figure 5. GPI-APs- cells in healthy individuals. 
Figure 6. Simulation of HSC differentiation in a model assuming a mosaic environment for 
the commitment of primitive progenitors recapitulates the clinical observation. 
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